Evidence map›Paper›PMID 38900939›Full record

ArticleCancer research2024

Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer.

Ganfei Xu, Rui Huang, Reziya Wumaier, Jiacheng Lyu, Minjing Huang, Yaya Zhang, Qingjian Chen, Wenting Liu, Mengyu Tao, Junjian Li and 10 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Understanding and targeting the tumour matrisome.Nature reviews. Clinical oncology · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Extracellular vesicles as modulators of cancer metabolism and microenvironment.Extracellular vesicles and circulating nucleic acids · 2026
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ganfei Xu *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0003-4707-9804
Rui Huang *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0002-3309-2867
Reziya Wumaier *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0002-7331-6212
Jiacheng LyuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0009-0008-8136-9657
Minjing HuangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0009-0004-4856-3467
Yaya ZhangDepartment of Oncology, State Key Laboratory of Systems Medicine for Cancer, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-6487-1732
Qingjian ChenDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0003-0628-3198
Wenting LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0009-0001-6563-1116
Mengyu TaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0002-1500-304X
Junjian LiDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0001-7970-4163
Zhonghua TaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0003-3975-3803
Bo YuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0001-6039-4249
Erxiang Xu910th Hospital of the People's Liberation Army Joint Logistics and Security Forces, Quanzhou, China.ORCID 0009-0005-6321-9338
Lingfeng Wang910th Hospital of the People's Liberation Army Joint Logistics and Security Forces, Quanzhou, China.ORCID 0000-0002-4366-155X
Guoying YuState Key Laboratory of Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Organ Fibrosis, College of Life Science, Henan Normal University, Xinxiang, China.ORCID 0000-0002-5273-4853
Olivier GiresDepartment of Otorhinolaryngology, LMU University Hospital, LUM Munich, Germany.ORCID 0000-0002-2292-7064
Lei ZhouSchool of Optometry, Department of Applied Biology and Chemical Technology, Research Centre for SHARP Vision, The Hong Kong Polytechnic University; Centre for Eye and Vision Research, Hong Kong, China.ORCID 0000-0001-5893-6002
Wei ZhuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-8040-4264
Chen DingDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0002-9589-9439
Hongxia WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0003-3481-6940

Funding

Fudan Original Research Personalized Support ProjectInnovation Research Team of High-level Local University in Shanghai SHSMU-ZLCX20211600Major Projects of Special Development Funds in Zhangjiang National Independent Innovation Demonstration Zone, Shanghai ZJ2019-ZD-004National Key Research and Development Program of China (NKPs) 2022YFA1303200National Key Research and Development Program of China (NKPs) 2023YFC2506400National Natural Science Foundation of China (NSFC) 32330062National Natural Science Foundation of China (NSFC) 82225038National Natural Science Foundation of China (NSFC) 82272828National Natural Science Foundation of China (NSFC) M-0349Program of Shanghai Academic Research Leader (Shanghai Academic Research Leader) 22XD1420100Science and Technology Innovation Plan Of Shanghai Science and Technology Commission () 23J21900900Shanghai Municipal Science and Technology Major Project 2023SHZDZX02
6 · The paper itself

Abstract

Analysis of extracellular vesicles (EV) is a promising noninvasive liquid biopsy approach for breast cancer detection, prognosis, and therapeutic monitoring. A comprehensive understanding of the characteristics and proteomic composition of breast cancer-specific EVs from human samples is required to realize the potential of this strategy. In this study, we applied a mass spectrometry-based, data-independent acquisition proteomic approach to characterize human serum EVs derived from patients with breast cancer (n = 126) and healthy donors (n = 70) in a discovery cohort and validated the findings in five independent cohorts. Examination of the EV proteomes enabled the construction of specific EV protein classifiers for diagnosing breast cancer and distinguishing patients with metastatic disease. Of note, TALDO1 was found to be an EV biomarker of distant metastasis of breast cancer. In vitro and in vivo analysis confirmed the role of TALDO1 in stimulating breast cancer invasion and metastasis. Finally, high-throughput molecular docking and virtual screening of a library consisting of 271,380 small molecules identified a potent TALDO1 allosteric inhibitor, AO-022, which could inhibit breast cancer migration in vitro and tumor progression in vivo. Together, this work elucidates the proteomic alterations in the serum EVs of breast cancer patients to guide the development of improved diagnosis, monitoring, and treatment strategies. Significance: Characterization of the proteomic composition of circulating extracellar vesicles in breast cancer patients identifies signatures for diagnosing primary and metastatic tumors and reveals tumor-promoting cargo that can be targeted to improve outcomes.

Indexed as

Biomarkers, TumorBreast NeoplasmsExtracellular VesiclesProteomicsAnimalsCell Line, TumorFemaleHumansMiceMice, NudePrognosisProteomeXenograft Model Antitumor AssaysBiomarkers, TumorProteome

Identifiers

PMID38900939
PMCPMC11443238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.